REVIEW article

Front. Immunol., 07 October 2020

Sec. Nutritional Immunology

Volume 11 - 2020 | https://doi.org/10.3389/fimmu.2020.584288

Host Factors of Favorable Intestinal Microbial Colonization

  • 1. Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hanover, Germany

  • 2. PRIMAL Consortium, Hanover, Germany

  • 3. Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hanover, Germany

Abstract

Gut microbial colonization starts with birth and initiates a complex process between the host and the microbiota. Successful co-development of both establishes a symbiotic mutual relationship and functional homeostasis, while alterations thereof predispose the individual life-long to inflammatory and metabolic diseases. Multiple data have been provided how colonizing microbes induce a reprogramming and maturation of immunity by providing crucial instructing information to the newborn immune system. Less is known about what host factors have influence on the interplay between intestinal immunity and the composition of the gut microbial ecology. Here we review existing evidence regarding host factors that contribute to a favorable development of the gut microbiome and thereby successful maturation of gut mucosal immunity.

Introduction

Several hundred bacterial species colonize the human gastrointestinal tract and live in a mutual relationship with the host and its immune system (1, 2). A healthy adult gut microbiota is stable and aids in digestion, detoxification and as a barrier against pathogens (3, 4). Importantly, the development of a health gut microbiota keeps the host immune system in a balanced state of tolerance and defense activity (Figure 1A). Though still ill defined, dysbiotic microbiome states are characterized by an altered microbiota composition of loss of diversity resulting in a bloom of pathobionts, loss of commensals, shift in metabolic capacities, and associate with the development of highly prevalent chronic inflammatory and metabolic diseases and/or an increased susceptibility to infections (5–9).

Figure 1

The postnatal period is particularly critical for the establishment of a healthy gut microbiota composition that promotes the postnatal maturation of gut mucosal and extra-intestinal immunity (10–15). The character of resulting host–microbe interactions determines what degree of gut homeostasis is achievable. Hornef and Torow recently proposed to implement the concept of the “neonatal window of opportunity” into the model of “layered immunity” as a timed succession of non-redundant phases during postnatal immune system maturation and establishment of host-microbial immune homeostasis (16). However, it often remains elusive whether a host factor or a microbiota state evolves as a result from the impact of the respective other feature or whether it represents a true driving force in this deeply interwoven developmental process. Clarification of this question is challenging and requires studies focusing on the beginning life with a high and longitudinal time resolution of effect sizes and directions.

Multiple data, especially those from experiments involving fecal transplants, demonstrated how colonizing microbes induce a reprogramming and maturation of immunity by providing crucial instructing information to the newborn immune system (10, 17–20) (Figure 1B). The importance of intestinal bacterial colonization for normal immune system development became particularly obvious by studies in germ-free mice that are lacking several immune functions (21–23) or the comparison of wild and laboratory mice (24). A surrogate in humans is antibiotic treatment that was shown to affect microbiome development of neonates and infants and translates into short- and long-term disorders characterized by dysregulated or impaired immune functions (25–33).

More challenging is the elucidation of the role of the host's state of immunity for the development of the gut microbiome (Figure 1C), especially that of infant-derived immune factors compared to maternally provided immune factors that supplement or impact on the infant's immune system. Moreover, the mode of action is often not clearly detangled in terms of microbiota-shaping by direct antimicrobial activity or indirectly via priming or regulation of neonatal mucosal immunity which then in turn impacts on the colonization or expansion of specific microbial communities. Finally, many studies have identified factors with immunoregulatory functions for the newborn's immune system but without further demonstration of a link to the microbiome development (those works will therefore not be discussed here).

Of course, exogenous factors such as the mode of delivery, infant feeding patterns, maternal diet, and environmental factors including drugs are also well-known to impact on the microbiome development either directly or indirectly by modulating the host's state of immunity. While these important microbiota-shaping exogenous directors have been extensively discussed elsewhere (34–36), we will focus in this review on endogenous host factors. Maternal (Table 1) and infant-derived (Table 2) host factors will be highlighted and evaluated regarding the present level of evidence on their role in shaping the development of the gut microbiome in humans and animals and thereby the maturation of gut mucosal immunity.

Table 1

Host factoraStudy subjectsMicrobiota-shaping effect derived from association studiesMicrobiota-shaping effect experimentally or per RCTb validatedMode of microbiota-shaping actioncReferences
Breast milk
IgAhuman, mouseyesyesdirect and indirect(37–40)
HMOsdhuman, mouse, hamster, pigyesyesdirect (indirect?)(35, 41–50)
α-Lactalbuminhuman, mouseinconclusiveinconclusivedirect(51–54)
Lactoferrinhuman, piginconclusiveinconclusivedirect(55–57)
Lysozymemouse, pigyesyesdirect(58–60)
TGF-βhumanyesnounknown(61)
S100A8/A9human, mouseyesyesdirect and indirect(62, 63)
Extracellular vesiclesmousenoyesindirect(58, 64)
Human milk microbiomehuman, mouseyesnodirect (indirect?)(65–69)
Obesityhumanyesnounknown(70, 71)

Studies providing evidence for the influence of maternal host factors on the postnatal development of the infant's gut microbiome.

a

Factors supplied by the mother and produced endogenously in the neonatal intestine are highlighted.

b

RCT, randomized controlled clinical trial.

c

Direct by antimicrobial or prebiotic activity or indirect by priming of mucosal immunity or unknown.

d

HMO, human milk oligosaccharides.

Table 2

Host factoraStudy subjectsMicrobiota-shaping effect derived from association studiesMicrobiota-shaping effect experimentally or per RCTb validatedMode of microbiota-shaping actioncReferences
Host genotypehuman, mouseyesnounknown(72–76)
Innate immune signaling
TLR5mouseyesyesindirect(77, 78)
IRAK-1mouseinconclusiveinconclusiveindirect(79)
TLR4 (S100A8/A9)human, mouseyesyesdirect and indirect(62, 63)
NOD2human, mouseyesnounknown(75, 80–82)
NLRP3mouseyesinconclusiveunknown(83)
NLRP6mouseyesyesindirect?(84–88)
Antimicrobial peptides
Defensinsmouseyesyesdirect(89)
Reg3dmouseinconclusiveyesdirect(90–94)
Mucinsmouseyesyesdirect(95–98)
Antimicrobial proteins
Lactoferrinhuman, piginconclusiveinconclusivedirect(55–57)
Lysozymemouse, pigyesyesdirect(58–60)
Others
IgAhumanyesnodirect and indirect(40, 99–101)
TGF-βhumanyesnounknown(61)
miRNAsmouseyesyesdirect (indirect?)(102–104)

Studies providing evidence for the influence of infant-derived host factors on the postnatal development of the infant's gut microbiome.

a

Factors supplied by the mother and produced endogenously in the neonatal intestine are highlighted.

b

RCT, randomized controlled clinical trial.

c

Direct by antimicrobial or prebiotic activity or indirect by priming of mucosal immunity or unknown.

d

Reg3, regenerating islet-derived protein 3 family.

Maternal Factors

Breast Milk

Human breast milk is the ideal nourishment for infants and has been shaped by evolution to contain essential nutrients and immunological components necessary for the neonate during its initial phase of life. Numerous studies indicate that breastfed neonates are better protected against infections, inflammatory disorders and allergies and show improved cognitive development compared to infants fed with formula (105). In the following we report human breast milk components of different substance classes with the strongest evidence for a capacity to modulate the developing microbiota either directly via antimicrobial or prebiotic activities or indirectly by modulating immune functions of the host.

Immunoglobulin A (IgA)

During the first months of life, breast milk is the predominant source of IgA as B cells generally do not populate the intestine until about 4 weeks of age (37, 106). In mice, early exposure to maternal soluble IgA via breast milk prevented the translocation of aerobic bacteria from the neonatal gut into draining lymph nodes (38). In human preterm infants, a high ratio of IgA-coated Enterobacteriaceae to uncoated Enterobacteriaceae was associated with a lower risk of NEC while a mouse model confirmed the NEC-protective effect of breast milk IgA (37). It is speculated that secretory IgA contributes to the creation of temporal and spatial niches and exerts a strong selection pressure on colonization along the gastrointestinal tract. IgA levels are particularly high in crypts. Agglutination and immune exclusion might primarily act against highly prevalent bacteria and thus favor colonization by minorities and microbial diversity (107). In addition, secretory IgA binds to components of the mucus (108) and co-localizes specifically with gut bacteria in the outer mucus layer (109). The outer mucus layer forms a distinct microbial niche colonized by bacteria with mucolytic capability (110). IgA-coated bacteria might be retained in the mucus layer, which reduces their shedding and promotes diverse colonization (107). In neonatal mice, secretory IgA dampened T cell-dependent immune responses against commensal bacteria (39) and was involved in the selective suppression of Proteobacteria during establishment of the early gut flora (40). A reduced IgA supply via breast milk during infancy came along with an altered gene expression profile of intestinal epithelial cells characterized by an increased expression of genes associated with intestinal inflammatory diseases in humans (38). By the age of weaning, the induction of a Gammaproteobacteria-specific IgA response partially contributes to the transition from a neonatal to a mature microbiota (40). Experiments in germfree mice showed that colonization with microbes from mice lacking IgA have persistent increased colonization with Gammaproteobacteria that results in sustained intestinal inflammation and increased susceptibility to neonatal and adult models of intestinal injury (40). Collectively, there is clear evidence in mice and humans that that IgA supplied via breast milk has direct and indirect beneficial effects on the developing gut microbiota.

Human Milk Oligosaccharides (HMOs)

HMOs are the third largest solid component of breast milk after lipids and lactose and known to have a bifidogenic effect on the infant's microbiome. HMOs promoted the growth of specific Bifidobacteria, supporting an early Bifidobacteria-dominated gut microbiome (35, 41, 42). The structure of some HMOs resembles that of epithelial pathogen receptors, enabling them to serve as a decoy receptor to prevent pathogen binding and enhance pathogen clearance (42). A mother's secretor status is genetically defined and determines the HMO concentration and profile in her breast milk (111–113). The abundance of Bifidobacteria in the intestinal microbiome of breastfed infants of non-secretor women was lower than in that of children of secretor women (43, 44). In preterm infants, colonization with Bifidobacterium breve was shown to depend on the composition of HMOs but not the mother's secretor status (45). Infant fecal HMO concentrations change over time and correlate with a shift in the fecal microbiota from a non-saccharolytic population dominated by commensals of the birth canal to a population dominated by saccharolytic microbes (46) Several randomized controlled trials showed that infants fed with a formula supplemented with the HMOs 2′-FL ± lacto-N-neotetraose or galacto-oligosaccharides develop a distinctive stool bacterial population compared to infants fed a control formula which is more similar to that of breastfed infants (increased colonization with Bifidobacteria and Lactobacillus and decreased colonization with pathobionts) and was accompanied by a lower plasma inflammatory cytokine concentrations (47–50). In vitro, HMOs prevented the intestinal epithelial attachment of enteropathogenic Escherichia (E.) coli but whether this was a direct or indirect effect remained elusive (114) With respect to the mode of action, HMOs were shown to modulate also toll-like receptor (TLR)-dependent proinflammatory signaling, while elevating cytokines involved in tissue repair and homeostasis (115–117). However, these effects could not be linked to the gut microbiota-shaping effect so far. Further mechanistic studies are required to understand how HMOs influence the development of the gut microbiota.

α-Lactalbumin

α-Lactalbumin is the major whey protein in breast milk and is digested in the small intestine (118). Several peptides released from α-lactalbumin during digestion have been proposed to elicit biological effects. In vitro studies demonstrated their antimicrobial activity toward potential pathogens as E. coli, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus epidermis, Streptococci, and Candida albicans as well as their prebiotic activity by stimulating the growth of Bifidobacteria (51–53). A study in mice showed significantly higher proportions of Lactobacillus, Parabacteroides and Bifidobacterium in animals fed a high-fat diet supplemented with α-lactalbumin compared to a control diet (54). However, only a few data have been published on the effects of α-Lactalbumin on developing gut microbiota communities in humans and remain inconclusive (119, 120).

Lactoferrin

Lactoferrin is a non-heme iron binding protein with direct microbial as well as immunomodulatory activities. Lactoferrin is digested to some extend in the infant's intestine yielding bioactive peptides (121). Degradation products of lactoferrin such as lactoferricin (122–125) or Lf(1–11) and lactoferrampin (126, 127) also showed strong bactericidal activity against various kinds of both Gram-positive and Gram-negative bacteria and might contribute to the following net effect of lactoferrin. Piglets fed recombinant human lactoferrin had a greater abundance of Lactobacillus and lower abundances of Veillonella and Escherichia-Shigella in the jejunum and of Actinobacillus in the ileum at 1 week resp. 3 weeks of life (55). Several in vitro studies have shown that human lactoferrin is able to stimulate the growth of Bifidobacteria (56, 57). In vivo, a bifidogenic effect of lactoferrin has also been suggested, but only for bovine and not for human lactoferrin (128), or based on a non-confounder-controlled association between fecal lactoferrin levels on day 3 of life with the amount of fecal Bifidobacteria and Lactobacilli in human infants (129). Clinical trials on the microbiota-shaping effect of the nutritional supplementation of newborn infants with bovine lactoferrin have reported conflicting results with no significant impact on the developing fecal microflora (130, 131) or reduction of pathobionts in a very small cohort of 21 very low birth weight preterm infants (132) or a minor contribution to the total Bifidobacterium population in 202 healthy term infants (133). Human lactoferrin exerts direct antibacterial and antiviral activities through iron depletion (134), interaction with microbial and target host cell surfaces (135) and by preventing the entry of viral particles into the host cells, either by blocking cellular receptors or by directly binding to the viral particles (136). Furthermore, lactoferrin modulates innate and adaptive immune responses thereby controlling the expression of different anti- and pro-inflammatory cytokines and chemokines [e.g., interleukin (IL)-4, IL-10, IL-1, IL-6, IL-12, tumor necrosis factor-α] which impacts on the growth, differentiation, activation and function of immune cells (136–138). Whether and how the immunomodulatory effects contribute to the microbiota-shaping effect or whether the latter primarily results from the antimicrobial activity of lactoferrin remains to be shown.

Lysozyme

Lysozyme is an antimicrobial protein secreted by glandular epithelial cells that functions by cleaving bacterial peptidoglycan, causing a loss of cellular membrane integrity and cell lysis. In adult sows, feeding of high amounts of lysozyme reduced the intestinal richness of E. coli and increased abundance of Lactobacillus amylovorus (58). Recombinant human lysozyme expressed at high level in milk of transgenic pigs inhibited the growth of E. coli in the duodenum of piglets (59). In transgenic mice, expression of recombinant human lysozyme promoted the growth of Bifidobacterium and inhibited the growth of Salmonella in the intestine (60). In humans, the role of lysozyme for a developing gut microbiome is unknown.

Transforming Growth Factor β (TGF-β)

There is only one study showing that breast milk cytokines TGF-β1 and TGF-β2 partially explains variation in gut microbial composition among human breast-fed neonates. Especially, high concentrations of TGF-β2 were associated with a richer microbiome with an increased abundance of several bacteria, including members of Streptococcaceae and Ruminococcaceae, and lower relative abundance of distinct Staphylococcaceae taxa in neonatal gut composition (61). The exact mode of the microbiota-shaping effect has not been clarified and experimentally validated yet.

S100A8/A9

The alarmins S100A8 and S100A9 are myeloid-related proteins. Upon extracellular release they typically form the heterodimer complex S100A8/A9, also known as calprotectin (139). Human breast milk contains exceeding high amounts of S100A8/A9 with the highest levels found after the vaginal delivery of a full-term neonate compared to birth of a preterm infant per cesarean section (62). S100A8/A9 proved to be an important mediator of the antimicrobial activity of breast milk, especially inhibiting the growth of manganese sensitive bacteria such as Staphylococcus aureus and group B streptococci (62). Willers et al. found that human infants with reduced levels of fecal S100A8/A9 during the first year of life had an altered development of the gut microbiome characterized by less abundant Actinobacteria including Bifidobacteriaceae but dominant colonization with Gammaproteobacteria, particularly opportunistic Enterobacteriaceae (63). This gut microbial state in turn translated into a higher risk of neonatal sepsis and development of obesity (33, 63). It could furthermore be demonstrated in mice that the high enteral supply of S100A8/A9 after birth primes a regulatory phenotype in lamina propria macrophages with a high expression of Cx3cr1, Il-10, and Tgf-β, that is followed by a stronger expansion of regulatory T cells in intestinal tissues and a restricted expansion of Enterobacteriaceae. A single feeding of S100A8 after birth prevented the excess expansion of Enterobacteriaceae as well as fatal sepsis in neonatal mice (63).

Extracellular Vesicles

Extracellular vesicles in breast milk may influence the establishment of the intestinal microbiota by altering the local immune response toward challenges from microbial colonization (105). Breast milk exosomes contain proteins, RNA, microRNA and long non-coding RNA (140–142). Profiling studies found these microRNAs to be related to multiple biological functions of a wide range of immunological pathways (143, 144). Likewise, proteomic analyses revealed that human breast milk extracellular vesicles include proteins involved in regulation of cell growth and controlling inflammatory signaling pathways (142). In addition to vesicles released by maternal cells (exosomes), a recent study revealed the presence of bacteria-derived extracellular vesicles in breast milk (145). Their vertical transfer or indirect involvement into the development of the infant's gut microbiota is possible but has not been shown yet. The presence of serum-derived extracellular vesicles impacted on epithelial and immune cell responses to the gut microbes Lactobacillus or Bifidobacterium and enhanced their aggregation and phagocytosis and modulated TLR-induced cellular responses (64). Whether breast milk extracellular vesicles have similar effects is not known yet. Feeding of bovine milk exosomes to young adult mice altered bacterial communities in the murine cecum (higher abundance of Tenericutes and Lachnospiraceae, lower abundance of Verrucomicrobiaceae) (58). Data on the influence of milk extracellular vesicles and their cargo on human infant's gut microbial communities are still lacking.

Human Milk Microbiota

Although not in a strict sense an endogenous maternal factor, the mother the human milk microbiota is at least mother-specific and represents therefore for the infant an endogenous factor in the broader sense. Human milk contains ~106 bacterial cells/mL. Commonly isolated microbiota in human milk are Staphylococcus, Streptococcus, Propionibacterium, Bifidobacterium, and Lactobacillus among others (146–150). The composition and variation of the human milk microbiota are associated with the maternal body mass index, parity, glucose tolerance status, mode of delivery, ethnicity, breast feeding practices, and other milk components (151, 152). The origin of bacteria in human milk is not well-established. Two different routes, which are probably not mutually exclusive, have been proposed: (i) surface skin contamination and retrograde flow during breastfeeding and (ii) translocation through a more speculative gut-mammary route (153). The assumption that microbes in breast milk contribute to the establishment of the infant intestinal microbiome is supported by several studies in mother-infant pairs using sequencing techniques and demonstrating that breast milk and term infants' feces share specific microbial strains of Bifidobacterium, Lactobacillus, Enterococcus, and Staphylococcus (65–69). In vitro and mouse studies demonstrated that several Lactobacillus strains isolated from human milk exert immune-modulatory effects on bone marrow-derived macrophages as well as antibacterial properties against pathogenic bacteria (149, 150). However, clear evidence for a colonization of human milk microbiota in the infant's intestine or an indirect impact of human milk microbiota on the developing intestinal microbiome has not been provided yet. Kim and Yi recently raised the question whether extracellular vesicles derived from the human milk microbiota are involved in the vertical transfer from mothers to their progeny (145), which remains unanswered to date.

Obesity

Neonates born to mothers with obesity showed a 50% reduction in the intestinal abundance of Gammaproteobacteria at 2 weeks of age compared with infants of normal-weight mothers (70). Furthermore, infants born to overweight mothers were found to have an increased abundance of Bacteroides and Staphylococcus at 1 and 6 months of age compared to infants of normal-weight mothers (71). Reasons might be the different and less diverse bacterial community in breast milk from mothers with obesity compared to normal-weight mothers, including higher levels of Staphylococcus and Akkermansia muciniphila and lower levels of Bifidobacterium (154, 155). Differences in the composition of hormones, cytokines and HMOs might also play a microbiota-shaping role (156, 157). These findings might even challenge the beneficial value of breast milk feeding in case of overweight mothers. This concern is corroborated by the data that antibiotic use in infants born to mothers with obesity reduced the risk of obesity, whereas antibiotic use in infants born to normal-weight mothers increased the risk of obesity (158). Another reason for the altered microbiome composition in infants born to obese mothers might be iron deficiency (157, 159, 160). Mothers with obesity and those with excess gestational weight gain as well as their infants are significantly more often iron deficient (161, 162). Several clinical and in vitro studies have demonstrated the impact of iron deficiency and supplementation on the gut microbiota composition and function and intestinal inflammation in infants and children (163–168). However, whether iron deficiency is the causative mechanism altering the postnatal gut microbiota colonization in infants of mothers with obesity needs to be further explored.

Infant Factors

Host Genotype

There is growing scientific evidence indicating that host genetics influence the acquisition and development of the infant gut microbiota (72–74). Studies in mice revealed that host genetics in the interplay with the diet shape the intestinal microbiota composition with individual genes and regulatory circuits only beginning to be identified (72, 73). Benson et al. found 18 quantitative trait loci in mice that show significant or suggestive genome-wide linkage with the relative abundances of specific microbial taxa (72). A study using three large human cohorts established a clear association between the host genotype and the gut microbiota state in adulthood. In this analysis, 58 single nucleotide polymorphisms (SNPs) at nine loci were associated with microbial taxa and a total of 33 loci were associated with functional units, with 21 loci associated with metabolic pathways and 12 loci associated with gene ontogeny categories. For example, variants of the LCT locus responsible for the human lactase production linked to the abundance of Bifidobacteria, while variants of the NOD2 locus had an impact on the pathway abundance of enterobactin biosynthesis which in turn strongly correlated with the abundance of E. coli (75). Another study in a large human twin cohort uncovered associations between heritable taxa and genes related to diet, metabolism, olfaction, barrier defense, and self/non-self-recognition (76). Summarized, linkage studies on associations between genetic variants and gut microbiota states point to possible important host factors that are crucial for the establishment of a healthy gut microbiome. For most of presently identified genetic trait loci further research is needed to confirm the relevance of these host factors for the development of the gut microbiome experimentally and in human infants.

Innate Immune Signaling

Toll-Like Receptors (TLRs)

Age-dependent differences exist for the intestinal expression of individual TLR receptors in mice and humans (77, 169). This fact already suggests TLR signaling playing a role for the postnatal development of the gut microbiome and evidence for this specific relationship is accumulating. Several mouse models with knock-downs or genetic variants targeting TLR-signaling pathways at different levels (MyD88, Tlr2, Tlr4, Tlr5, Tlr9, Trif , NF-kB-pathway) are characterized by spontaneous or permissive colitis (20, 170–181). We learned from these mouse models how critical commensal-mediated TLR-signaling is for the training and maintenance of gut mucosal immunity and integrity. The host's primary phenotype and programming of TLR-signaling is conversely probably likewise important for the development of the gut microbiome. However, this reverse effect order has been clarified only for a few TLR-related host factors and barely in humans.

For the flagellin receptor TLR5 it has been clearly shown that its transient expression on the gut epithelium of neonatal mice contributes to the establishment of a favorable gut microbiota that lowers the risk of intestinal inflammatory injuries (77, 78). Fulde et al. demonstrated in mice that a TLR5-mediated epithelial production of the regenerating islet-derived protein 3 γ (REG3γ) is critical to restrict the colonizing of flagellated bacteria. This host-mediated regulatory circuit of bacterial colonization acts solely during the early neonatal period but influences life-long microbiota composition. The relevance of TLR5-signaling on the gut microbiota development in human infants has not been demonstrated yet.

Chassin et al. demonstrated that the microRNA-146a-mediated translational repression and proteolytic degradation of the essential TLR signaling molecule interleukin 1 receptor associated kinase 1 (IRAK1), an integral element of MyD88-dependent TLR-signaling pathways, induces intestinal epithelial innate immune tolerance toward lipopolysaccharide (LPS) of Gram-negative bacteria. It furthermore protects murine neonates against epithelial damage from oral challenge with E. coli (79), suggesting that IRAK1 has a beneficial impact on the established microbiota. In contrast, however, 16S rRNA profiling of stool samples revealed miR-146a-deficient mice having a rather favorable gut microbiota composition protecting against Listeria monocytogenes infection compared to wild-type mice with decreased levels of the Proteobacteria phylum, Prevotellaceae family, and Parasutterella genus, and significantly increased short-chain fatty acid producing bacteria, including the genera Alistipes, Blautia, Coprococcus_1, and Ruminococcus_1 (102). Thus, the role of IRAK1 for the development of the gut microbiota remains to be clarified and also elucidate in humans.

The alarmins S100A8 and S100A9 are endogenous TLR4 ligands (182). Next to their high supply via breast milk (62), S100A8 and S100A9 are also endogenously produced in intestinal tissues by lamina propria macrophages, in infants at significantly higher levels than in intestinal tissues from adults (63). Studies in S100a9 knock-out mice and cross-fostering settings delineated the mode of action. S100A8/A9-mediated TLR4-signaling during the neonatal period tolerized the inflammatory responsivity of lamina propria macrophages and increased the expression tonus of regulatory genes like IL-10 and transforming growth factor-β. This regulatory macrophage phenotype impacted on the developing microbiota in mouse and humans as outlined above. To achieve full effects regarding immunoregulation and modulation of gut colonization the additional supply of S100A8/A9 via breast milk was mandatory (63).

NOD-Like Receptors (NLRs)

Similar as in the case of TLRs, murine NLR knock-out models (Nod2, Nlrp3, Nlrp6, Nlrc4, caspase 1) with increased (albeit partly controversial) susceptibility in different colitis models (183–188) point to NLRs as important host factors for the establishment of a protective gut microbiota. However, for most factors this assumption awaits experimental approval.

Mutations in the peptidoglycan sensor NOD2 locus represent one of the most important genetic risk factors for inflammatory bowel disease (IBD) (189, 190). As mentioned above, genetic variants of the NOD2 locus in humans correlated with the intestinal abundance of E. coli (75). In two cohorts of adult patients with IBD, a significant positive correlation was found between the number of IBD risk alleles in the NOD2 exon and the relative abundance of Enterobacteriaceae (80). Two recent studies in mice demonstrated that NOD2 influences microbial resilience with prolonged alterations of the microbiota in Nod2-deficient mice after antibiotic treatment, in case of neonatally treated mice resulting in an increased susceptibility to colitis in adulthood (81, 82). However, experimental evidence for NOD2 shaping the primary development of the gut microbiota in neonates and infants and the related mode of action is still lacking.

For NLRP3 it could recently been shown that the compositions of the gut microbiota in Nlrp3 knock-out mice and wild-type mice were significantly different (83). At the genus level, NLRP3 deficiency decreased the relative abundance of Bacteroides but increased the abundance of Desulfovibrio, Mucispirillum, Oscillospira, and Ruminococcus. Surprisingly, fecal microbiota transplantation from Nlrp3 knock-out mice significantly ameliorated depressive-like behaviors of recipient wild-type mice in a chronic stress model suggesting that restriction of NLRP3-dependent inflammasome signaling is important to ensure healthy gut microbiota development. For a final evaluation of the role and mode of action of NLRP3 regarding its impact on developing gut microbiota compositions further clarifying data in mice as well as humans is desirable.

Elinav et al. were the first group demonstrating that the lack of intestinal epithelial NLRP6-dependent inflammasome activity results in an expansion of the bacterial phyla Bacteroidetes and TM7 and that this microbiota state exacerbates chemical colitis (84). This microbiota-shaping effect was later ascribed, but not directly linked, to a regulating impact of NLRP6 on mucus secretion by goblet cells (85). However, littermate-controlled mouse studies then dismissed the impact of NLRP6-dependent inflammasomes on the composition of the commensal gut microbiota (86, 87). This conflict could be detangled by showing that NLRP6 matters in dependence of the microbial community structure. In pathobiont-free conditions WT and Nlrp6-deficient mice had a similar microbiota while upon introduction of pathobionts a high prevalence, specifically of Prevotellaceae, Verrucomicrobiaceae, and Helicobacteraceae, in Nlrp6-deficient mice became obvious (88). This finding was also largely in line with the previous findings (84). Demonstration of the biological relevance of NLRP6 shaping the microbiota development in humans would now be convincing.

Antimicrobial Peptides (AMPs)

The anatomical distribution of AMPs in mice and humans shows age-dependent differences (77, 191). In fetal intestine AMPs are already expressed prenatally and levels increase with gestational age (192, 193). Major AMP families are cathelicidins, α-defensins, and β-defensins, lectins, and mucins (194, 195). The peptides are stored in vacuoles of granulocytes and/or epithelial cells ready to be secreted upon microbial stimulation. In addition to their ability to kill bacteria by disrupting critical membrane functions, many AMPs have chemotactic and immunomodulatory activities (194, 196). It is evident that induced expression of AMPs is frequently an integral part of a response to a microbial challenge, reflecting how colonizing microbes train the host's immunity (197, 198). Conversely, though not in humans but at least in mice, there is also evidence that the levels and composition of AMPs in the gut can regulate the development of the microbiota.

In human α-defensin 5 (HD-5) transgenic mice significant changes in the microbiota composition were observed compared to wild-type littermate controls, specifically a lower relative abundance of Firmicutes and higher percentages of Bacteroidetes (89). Human REG3α and its murine homolog REG3γ are C-type soluble, carbohydrate-binding lectins found throughout the small intestinal epithelium, and in the large intestine in response to infection and inflammation (199). Bacterial binding (90, 91) and membrane permeabilization (92) are proposed to be important for the bactericidal activity of REG3. Hitherto shown effects of REG3α resp. REG3γ on the gut microbiota are not consistent, most likely due to diverse confounders like REG3 expression levels, age, and initial health condition. In a murine model of alcoholic steatohepatitis, intestinal REG3γ was protective by reducing the mucosa-associated microbiota and preventing bacterial translocation (93). On the other side, the fecal microbiota of mice that express human REG3α in hepatocytes (hREG3α travels via the bile to the intestinal lumen) showed a significant shift in microbiota composition compared to control mice, with an enrichment of Clostrididales (Ruminococcaceae, Lachnospiraceae) and depletion of Bacteroidetes (Prevotellaceae) (94). These mice were less sensitive to colitis, suggesting that increased intestinal levels of REG3α might impair the development of a healthy gut microbiota state.

Mucins are the main structural components of mucus, the biopolymer found throughout the gastrointestinal tract (199). Some commensal intestinal bacteria, including Bacteroidetes, are mucolytic and use mucin glycoproteins as an energy source (95, 96). Therefore, mucins have been proposed to play an important role in shaping microbial communities at the intestinal luminal surface. Recent studies in mice suggest a correlation between changes in mucin glycosylation profiles and deviations of overall microbial community ecology as well as altered abundances of specific microbes (97, 98). Mice lacking terminal fucose residues in their distal gut mucins showed significantly higher abundance of members of the genera Parabacteroides, Eubacterium, Parasutterella, Bacteroides, and family Lachnospiraceae and lower abundance of an unclassified genus within the order Clostridiales (97). Changes in mucus glycosylation due to loss of core 1-derived O-glycans in mice led to inverse shifts in the abundance of the phyla Bacteroidetes and Firmicutes (98).

Summarized, further supporting studies in mice and particularly first evidences in humans are warranted to verify the host-microbiome direction of the AMP-microbiota axis.

Antimicrobial Proteins

Antimicrobial proteins play important roles in the first line of defense, by either killing pathogens directly, or by contributing to an efficient immune response to eliminate pathogens. Most abundant antimicrobial proteins in humans are lactoferrin and lysozyme, both of which are also contained in breast milk. Their potential to influence the postnatal development of the gut microbiome composition has been discussed above. Whether the endogenous production of these proteins is important for the putative microbiota-shaping effect or to what extent the endogenous production contributes to the effect of the maternal supply of these factors has not been clarified so far. However, the lack of considering also the endogenous production and levels of these factors might have hampered the significance of effect sizes of the exogenous supply in previous studies.

Others

Immunoglobulin A (IgA)

The knowledge on how IgA impacts on the developing gut microbiota is mainly based on studies with a focus on the IgA supply via breast milk and has been outlined above. However, also the endogenous IgA production by the infant is of relevance in this context. Patients with common variable immunodeficiency (CVID) showed a large shift in the microbiota (reduced abundance of Actinobacteria and Firmicutes and increased abundance of Gammaproteobacteria) which was particularly pronounced in patients with undetectable serum IgA and also found in patients with selective IgA deficiency (99–101). In patients with selective IgA deficiency, metagenomic analyses revealed pathobiont expansion (e.g., Gammaproteobacteria including E. coli) and depletion in some typically beneficial symbionts belonging to the Bacteroidetes and Firmicutes phylum (100, 101, 200, 201).

Transforming Growth Factor β (TGF-β)

TGF-β is a regulatory cytokine ubiquitously produced by immune cells and epithelial cells in intestinal tissues. While breast milk levels of TGF-β correlated with the neonate's microbiota composition (61), the role endogenously produced TGF-β plays in this context has not been explored so far.

MicroRNA (miRNA)

MicroRNAs are single-stranded non-coding RNA molecules with a length varying between 18 and 23 nucleotides that operate in post-transcriptional regulation of gene expression (202). miRNAs are found in various body fluids as plasma, urine and breast milk as well as in human feces (103, 143, 203, 204). Fecal miRNAs are secreted by intestinal epithelial cells (IEC), particularly homeodomain-only protein homeobox (HOPX)-positive cells, such as goblet and Paneth cells (103). In vitro studies revealed that specific fecal miRNAs were able to enter Fusobacterium (F.) nucleatum and E. coli, regulate bacterial gene transcripts, and affect bacterial growth. Furthermore, IEC-miRNA deficient mice showed uncontrolled gut microbiota compared to wild-type mice and exacerbated colitis. Wild-type fecal miRNA transplantation restored fecal microbes and ameliorated colitis (103). Moreover, the abundances of the phyla Bacteroidetes, Firmicutes, Actinobacteria, Bacteroidetes, Cyanobacteria, and Proteobacteria correlated with distinct murine miRNA levels (104). Another murine model revealed differing gut microbiota compositions with decreased levels of the Proteobacteria phylum, Prevotellaceae family, and Parasutterella genus, and significantly increased short-chain fatty acid producing bacteria, including the genera Alistipes, Blautia, Coprococcus_1, and Ruminococcus_1 in miR-146a-deficient mice relative to wild-type mice (102). Whether this is an indirect effect linked to the miR-146a-mediated induction of intestinal epithelial innate immune tolerance (79, 205) or due to a direct microbial activity of miR-146a has not been detangled yet. Ji et al. demonstrated that human fecal miRNAs associated with inflammatory bowel disease have diverse effects on the proliferative activity of the intestinal bacteria F. nucleatum, E. coli and segmental filamentous bacteria following the uptake of these miRNAs by the microorganisms (206). Of note, data on the influence of fecal miRNAs on the developing intestinal microbiome in neonates and infants are missing to date. Moreover, for miRNAs found in breast milk (143) neither a microbiota-shaping effect nor correspondences with microbiota-shaping fecal miRNAs could be demonstrated so far (wherefore they have not been listed in Table 1 but highlighted in Table 2 as factors supplied by the mother and produced endogenously in the neonatal intestine).

Concluding Remarks

Acknowledging that the establishment of a diverse and stable gut microbiota during the first years of life is crucial for life-long immune homeostasis, acquisition of tolerance, resistance against pathogens, and overall health fueled recent research work for factors that regulate the development of a health-promoting host-microbiota relationship. Present studies proposing host factors possibly important in this process of gut microbiome development differ regarding the therefore provided level of evidence. The spectrum of proof ranges from sole assumptions based on known biological functions, e.g., factors with antimicrobial activity, through association studies of host factor levels or genetic variants with specific microbiota states up to the experimental confirmation of the microbiota-shaping function, at best including delineation of the related mode of action. Moreover, the studies that provide functional data are mostly restricted to investigations in the mouse but lack demonstration of the biological relevance of the respective host factor in humans. Only if the latter condition is met together with a high grade of functional evidence for a beneficial microbiota-shaping effect this would allow and encourage translation of the concept into a clinical trial. Currently, only a few factors (IgA, HMOs, and S100A8/A9) meet these criteria. Further studies are needed to advance existing data or to unravel novel host factors important for a favorable postnatal development of the gut microbiome. Unveiling such endogenous mechanisms of microbiota regulation is important as they are highly attractive candidates for exploiting nature's principles for effective intervention strategies to ensure the development of health.

Statements

Author contributions

SP and DV equally conceptualized and composed the manuscript. All authors contributed to the article and approved the submitted version.

Funding

SP was supported by the Ellen-Schmidt-Stipend and a HiLF-grant of Hannover Medical School. The Volkswagen Foundation (Az 90 005), the Appenrodt Foundation and the Deutsche Forschungsgemeinschaft (DFG) (VI 538/6-1), and the DFG under Germany's Excellence Strategy-EXC 2155 RESIST-Project ID 39087428 supported research in this area.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1.

    RoundJLMazmanianSK. The gut microbiome shapes intestinal immune responses during health and disease. Nat Rev Immunol. (2009) 9:313–23. 10.1038/nri2515

  • 2.

    NicholsonJKHolmesEKinrossJBurcelinRGibsonGJiaWet al. Host-gut microbiota metabolic interactions. Science. (2012) 336:1262–7. 10.1126/science.1223813

  • 3.

    BäckhedFLeyRESonnenburgJLPetersonDAGordonJI. Host-bacterial mutualism in the human intestine. Science. (2005) 307:1915–20. 10.1126/science.1104816

  • 4.

    TanakaMNakayamaJ. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int. (2017) 66:515–22. 10.1016/j.alit.2017.07.010

  • 5.

    TurnbaughPJLeyREMahowaldMAMagriniVMardisERGordonJI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. (2006) 444:1027–31. 10.1038/nature05414

  • 6.

    QinJLiYCaiZLiSZhuJZhangFet al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. (2012) 490:55–60. 10.1038/nature11450

  • 7.

    FrankDNSt AmandALFeldmanRABoedekerECHarpazNPaceNR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. (2007) 104:13780–5. 10.1073/pnas.0706625104

  • 8.

    GensollenTBlumbergRS. Correlation between early-life regulation of the immune system by microbiota and allergy development. J Allergy Clin Immunol. (2017) 139:1084–91. 10.1016/j.jaci.2017.02.011

  • 9.

    GluckmanPDHansonMACooperCThornburgKL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. (2008) 359:61–73. 10.1056/NEJMra0708473

  • 10.

    GensollenTIyerSSKasperDLBlumbergRS. How colonization by microbiota in early life shapes the immune system. Science. (2016) 352:539–44. 10.1126/science.aad9378

  • 11.

    MacphersonAJAgüeroMG deGanal-VonarburgSC. How nutrition and the maternal microbiota shape the neonatal immune system. Nat Rev Immunol. (2017) 17:508–17. 10.1038/nri.2017.58

  • 12.

    TorowNMarslandBJHornefMWGollwitzerES. Neonatal mucosal immunology. Mucosal Immunol. (2017) 10:5–17. 10.1038/mi.2016.81

  • 13.

    MenckebergCLHolJSimons-OosterhuisYRaatgeepHRde RuiterLFLindenbergh-KortleveDJet al. Human buccal epithelium acquires microbial hyporesponsiveness at birth, a role for secretory leukocyte protease inhibitor. Gut. (2015) 64:884–93. 10.1136/gutjnl-2013-306149

  • 14.

    ClaudECLuLAntonPMSavidgeTWalkerWACherayilBJ. Developmentally regulated IkappaB expression in intestinal epithelium and susceptibility to flagellin-induced inflammation. Proc Natl Acad Sci USA. (2004) 101:7404–8. 10.1073/pnas.0401710101

  • 15.

    KasaharaKMatsumuraYUiKKasaharaKKomatsuYMikasaKet al. Intranasal priming of newborn mice with microbial extracts increases opsonic factors and mature CD11c+ cells in the airway. Am J Physiol Lung Cell Mol Physiol. (2012) 303:L834–43. 10.1152/ajplung.00031.2012

  • 16.

    HornefMWTorowN. 'Layered immunity' and the 'neonatal window of opportunity' - timed succession of non-redundant phases to establish mucosal host-microbial homeostasis after birth. Immunology. (2020) 159:15–25. 10.1111/imm.13149

  • 17.

    HooperLVMacphersonAJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. (2010) 10:159–69. 10.1038/nri2710

  • 18.

    Gomez de AgüeroMGanal-VonarburgSCFuhrerTRuppSUchimuraYLiHet al. The maternal microbiota drives early postnatal innate immune development. Science. (2016) 351:1296–302. 10.1126/science.aad2571

  • 19.

    BelkaidYHarrisonOJ. Homeostatic immunity and the microbiota. Immunity. (2017) 46:562–76. 10.1016/j.immuni.2017.04.008

  • 20.

    Rakoff-NahoumSPaglinoJEslami-VarzanehFEdbergSMedzhitovR. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. (2004) 118:229–41. 10.1016/j.cell.2004.07.002

  • 21.

    PurchiaroniFTortoraAGabrielliMBertucciFGiganteGIaniroGet al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. (2013) 17:323–33.

  • 22.

    MacphersonAJHarrisNL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. (2004) 4:478–85. 10.1038/nri1373

  • 23.

    AtarashiKNishimuraJShimaTUmesakiYYamamotoMOnoueMet al. ATP drives lamina propria T(H)17 cell differentiation. Nature. (2008) 455:808–12. 10.1038/nature07240

  • 24.

    AbolinsSKingECLazarouLWeldonLHughesLDrescherPet al. The comparative immunology of wild and laboratory mice, Mus musculus domesticus. Nat Commun. (2017) 8:14811. 10.1038/ncomms14811

  • 25.

    ZeissigSBlumbergRS. Life at the beginning: perturbation of the microbiota by antibiotics in early life and its role in health and disease. Nat Immunol. (2014) 15:307–10. 10.1038/ni.2847

  • 26.

    GibsonMKWangBAhmadiSBurnhamCATarrPIWarnerBBet al. Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome. Nat Microbiol. (2016) 1:16024. 10.1038/nmicrobiol.2016.24

  • 27.

    CottenCMTaylorSStollBet al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. (2009) 123:58–66. 10.1542/peds.2007-3423

  • 28.

    KuppalaVSMeinzen-DerrJMorrowALSchiblerKR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr. (2011) 159:720–5. 10.1016/j.jpeds.2011.05.033

  • 29.

    AlexanderVNNorthrupVBizzarroMJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr. (2011) 159:392–7. 10.1016/j.jpeds.2011.02.035

  • 30.

    Hoskin-ParrLTeyhanABlockerAHendersonAJ. Antibiotic exposure in the first two years of life and development of asthma and other allergic diseases by 7.5 yr: a dose-dependent relationship. Pediatr Allergy Immunol. (2013) 24:762–71. 10.1111/pai.12153

  • 31.

    LamontRFMøller LuefBStener JørgensenJ. Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally. F1000Res. (2020) 9:F1000. 10.12688/f1000research.19954.1

  • 32.

    OosterlooBCVan't LandBde JagerWRuttenNBKlöppingMGarssenJet al. Neonatal antibiotic treatment is associated with an altered circulating immune marker profile at year of age. Front Immunol. (2020) 10:2939. 10.3389/fimmu.2019.02939

  • 33.

    GraspeuntnerSWaschinaSKünzelSTwisselmannNRauschTKCloppenborg-SchmidtKet al. Gut dysbiosis with bacilli dominance and accumulation of fermentation products precedes late-onset sepsis in preterm infants. Clin Infect Dis. (2019) 69:268–77. 10.1093/cid/ciy882

  • 34.

    MilaniCDurantiSBottaciniFCaseyETurroniFMahonyJet al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev. (2017) 81:e00036–17. 10.1128/MMBR.00036-17

  • 35.

    VandenplasYCarnielliVPKsiazykJSanches LunaMMigachevaNMosselmansJMet al. Factors affecting early-life intestinal microbiota development. Nutrition. (2020) 78:110812. 10.1016/j.nut.2020.110812

  • 36.

    GalazzoGvan BestNBervoetsLDapaahIOSavelkoulPHHornefMW; GI-MDH consortiumet al. Development of the microbiota and associations with birth mode, diet, and atopic disorders in a longitudinal analysis of stool samples, collected from infancy through early childhood. Gastroenterology. (2020) 158:1584–96. 10.1053/j.gastro.2020.01.024

  • 37.

    GopalakrishnaKPMacadangdangBRRogersMBTometichJTFirekBABakerRet al. Maternal IgA protects against the development of necrotizing enterocolitis in preterm infants. Nat Med. (2019) 25:1110–5. 10.1038/s41591-019-0480-9

  • 38.

    RogierEWFrantzALBrunoMECWedlundLCohenDAStrombergAJet al. Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. Proc Natl Acad Sci USA. (2014) 111:3074–9. 10.1073/pnas.1315792111

  • 39.

    KochMAReinerGLLugoKAKreukLSStanberyAGAnsaldoEet al. Maternal IgG and IgA antibodies dampen mucosal T helper cell responses in early life. Cell. (2016) 165:827–41. 10.1016/j.cell.2016.04.055

  • 40.

    MirpuriJRaetzMSturgeCRWilhelmCLBensonASavaniRCet al. Proteobacteria-specific IgA regulates maturation of the intestinal microbiota. Gut Microbes. (2014) 5:28–39. 10.4161/gmic.26489

  • 41.

    UnderwoodMAGermanJBLebrillaCBMillsDA. Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatr Res. (2015) 77:229–35. 10.1038/pr.2014.156

  • 42.

    VandenplasYBergerBCarnielliVPKsiazykJLagströmHSanchez LunaMet al. Human milk oligosaccharides: 2'-fucosyllactose. (2'-FL) and lacto-n-neotetraose. (LNnT) in infant formula. Nutrients. (2018) 10:1161. 10.3390/nu10091161

  • 43.

    LewisZTTottenMSSmilowitzJTPopovicMParkerELemayDGet al. Maternal fucosyltransverase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome. (2015) 3:13. 10.1186/s40168-015-0071-z

  • 44.

    Smith-BrownPMorrisonMKrauseLDaviesPS. Mothers secretor status affects development of childrens microbiota composition and function: a pilot study. PLoS ONE. (2016) 11:e0161211. 10.1371/journal.pone.0161211

  • 45.

    UnderwoodMADavisJCCKalanetraKMGehlotSPatoleSTancrediDJet al. Digestion of human milk oligosaccharides by bifidobacterium breve in the premature infant. J Pediatr Gastroenterol Nutr. (2017) 65:449–55. 10.1097/MPG.0000000000001590

  • 46.

    De LeozMLKalanetraKMBokulichNAStrumJSUnderwoodMAGermanJBet al. Human milk glycomics and gut microbial genomics in infant feces show a correlation between human milk oligosaccharides and gut microbiota: a proof-of-concept study. J Proteome Res. (2015) 14:491–502. 10.1021/pr500759e

  • 47.

    PuccioGAllietPCajozzoCJanssensECorselloGSprengerNet al. Effects of infant formula with human milk oligosaccharides on growth and morbidity: a randomized multicenter trial. J Pediatr Gastroenterol Nutr. (2017) 64:624–31. 10.1097/MPG.0000000000001520

  • 48.

    SteenhoutPSperisenPMartinFPSprengerNWernimontSPecquetSet al. Term infant formula supplemented with human milk oligosaccharides. (2′Fucosyllactose and Lacto-N-neotetraose) shifts stool microbiota and metabolic signatures closer to that of breastfed infants. FASEB J. (2016) 30:S1. 10.1096/fasebj.30.1_supplement.275.7

  • 49.

    GoehringKCMarriageBJOliverJSWilderJABarrettEGBuckRH. Similar to those who are breastfed, infants fed a formula containing 2'-fucosyllactose have lower inflammatory cytokines in a randomized controlled trial. J Nutr. (2016) 146:2559–66. 10.3945/jn.116.236919

  • 50.

    GiovanniniMVerduciEGregoriDBallaliSSoldiSGhisleniDet al. PLAGOS Trial Study Group. Prebiotic effect of an infant formula supplemented with galacto-oligosaccharides: randomized multicenter trial. J Am Coll Nutr. (2014) 33:385–93. 10.1080/07315724.2013.878232

  • 51.

    BrückWMGraverholtGGibsonGR. Use of batch culture and a two-stage continuous culture system to study the effect of supplemental α-lactalbumin and glycomacropeptide on mixed populations of human gut bacteria. FEMS Microbiol Ecol. (2002) 41:231–7. 10.1016/S0168-6496(02)00296-9

  • 52.

    BrückWMGraverholtGGibsonGR. A two-stage continuous culture system to study the effect of supplemental α-lactalbumin and glycomacropeptide on mixed cultures of human gut bacteria with entero-pathogenic Escherichia coli and salmonella serotype typhimurium. J Appl Microbiol. (2003) 95:44–53. 10.1046/j.1365-2672.2003.01959.x

  • 53.

    PellegriniAThomasUBramazNHunzikerPvon FellenbergR. Isolation and identification of three bactericidal domains in the bovine a-lactalbumin molecule. Biochim Biophys Acta. (1999) 1426:439–48. 10.1016/S0304-4165(98)00165-2

  • 54.

    BoscainiSCabrera-RubioRSpeakmanJRCotterPDCryanJFNilaweeraKN. Dietary α-lactalbumin alters energy balance, gut microbiota composition and intestinal nutrient transporter expression in high-fat diet-fed mice. Br J Nutr. (2019) 121:1097–107. 10.1017/S0007114519000461

  • 55.

    HuPZhaoFZhuWWangJ. Effects of early-life lactoferrin intervention on growth performance, small intestinal function and gut microbiota in suckling piglets. Food Funct. (2019) 10:5361–73. 10.1039/C9FO00676A

  • 56.

    KimWSTanakaTKumuraHKimGYKwonIKGohJSet al. Growth promoting effects of lactoferrin on L. acidophilus and Bifidobacterium spp. Biometals. (2004) 17:279–83. 10.1023/B:BIOM.0000027705.57430.f1

  • 57.

    LiepkeCAdermannKRaidaMMagertHJForssmannWGZuchtHD. Human milk provides peptides highly stimulating the growth of bifidobacteria. Eur J Biochem. (2002) 269:712–8. 10.1046/j.0014-2956.2001.02712.x

  • 58.

    ZhouFPazHASadriMCuiJKachmanSDFernandoSCet al. Dietary bovine milk exosomes elicit changes in bacterial communities in C57BL/6 mice. Am J Physiol Gastrointest Liver Physiol. (2019) 317:G618–24. 10.1152/ajpgi.00160.2019

  • 59.

    LuDLiQWuZShangSLiuSWenXet al. High-level recombinant human lysozyme expressed in milk of transgenic pigs can inhibit the growth of Escherichia coli in the duodenum and influence intestinal morphology of sucking pigs. PLoS ONE. (2014) 9:e89130. 10.1371/journal.pone.0089130

  • 60.

    DanLLiuSShangSZhangHZhangRLiN. Expression of recombinant human lysozyme in bacterial artificial chromosome transgenic mice promotes the growth of Bifidobacterium and inhibits the growth of Salmonella in the intestine. J Biotechnol. (2018) 272–3:33–39. 10.1016/j.jbiotec.2018.03.005

  • 61.

    SitarikARBobbittKRHavstadSLFujimuraKELevinAMZorattiEMet al. Breast milk transforming growth factor β is associated with neonatal gut microbial composition. Pediatr Gastroenterol Nutr. (2017) 65:e60–7. 10.1097/MPG.0000000000001585

  • 62.

    PirrSRichterMFehlhaberBPagelJHärtelCRothJet al. High amounts of S100-alarmins confer antimicrobial activity on human breast milk targeting pathogens relevant in neonatal sepsis. Front Immunol. (2017) 8:1822. 10.3389/fimmu.2017.01822

  • 63.

    WillersMUlasTVöllgerLVoglTHeinemannASPirrSet al. S100A8 and S100A9 are important for postnatal development of gut microbiota and immune system in mice and infants. Gastroenterology. (2020) S0016-5085(20)35058-7. 10.1053/j.gastro.2020.08.019

  • 64.

    van BergenhenegouwenJKraneveldADRuttenLKettelarijNGarssenJVosAP. Extracellular vesicles modulate host-microbe responses by altering TLR2 activity and phagocytosis. PLoS ONE. (2014) 9:e89121. 10.1371/journal.pone.0089121

  • 65.

    FerrettiPPasolliETettAAsnicarFGorferVFediSet al. Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome. Cell Host Microbe. (2018) 24:133–45.e5. 10.1016/j.chom.2018.06.005

  • 66.

    MurphyKCurleyDO'CallaghanTFO'SheaCADempseyEMO'ToolePWet al. The composition of human milk and infant faecal microbiota over the first three months of life: a pilot study. Sci Rep. (2017) 7:40597. 10.1038/srep40597

  • 67.

    AsnicarFManaraSZolfoMTruongDTScholzMArmaniniFet al. Studying vertical microbiome transmission from mothers to infants by strain-level metagenomic profiling. mSystems. (2017) 2:e00164–16. 10.1128/mSystems.00164-16

  • 68.

    PannarajPSLiFCeriniCBenderJMYangSRollieAet al. Association between breast milk bacterial communities and establishment and development of the infant gut microbiome. JAMA Pediatr. (2017) 171:647–54. 10.1001/jamapediatrics.2017.0378

  • 69.

    JostTLacroixCBraeggerCPRochatFChassardC. Vertical mother-neonate transfer of maternal gut bacteria via breastfeeding. Environ Microbiol. (2014) 16:2891–904. 10.1111/1462-2920.12238

  • 70.

    LemasDJYoungBEBakerPR IITomczikACSoderborgTKHernandezTLet al. Alterations in human milk leptin and insulin are associated with early changes in the infant intestinal microbiome. Am J Clin Nutr. (2016) 103:1291–300. 10.3945/ajcn.115.126375

  • 71.

    ColladoMCIsolauriELaitinenKSalminenS. Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy. Am J Clin Nutr. (2010) 92:1023–30. 10.3945/ajcn.2010.29877

  • 72.

    BensonAKKellySALeggeRMaFLowSJKimJet al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci USA. (2010) 107:18933–8. 10.1073/pnas.1007028107

  • 73.

    LeamyLJKellySANietfeldtJLeggeRMMaFHuaKet al. Host genetics and diet, but not immunoglobulin A expression, converge to shape compositional features of the gut microbiome in an advanced intercross population of mice. Genome Biol. (2014) 15:552. 10.1186/s13059-014-0552-6

  • 74.

    TurpinWEspin-GarciaOXuWSilverbergMSKevansDSmithMIet al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat Genet. (2016) 48:1413–7. 10.1038/ng.3693

  • 75.

    BonderMJKurilshikovATigchelaarEFMujagicZImhannFVilaAVet al. The effect of host genetics on the gut microbiome. Nat Genet. (2016) 48:1407–12. 10.1038/ng.3663

  • 76.

    GoodrichJKDavenportERBeaumontMJacksonMAKnightROberCet al. Genetic determinants of the gut microbiome in UK twins. Cell Host Microbe. (2016) 19:731–43. 10.1016/j.chom.2016.04.017

  • 77.

    FuldeMSommerFChassaingBvan VorstKDupontAHenselMet al. Neonatal selection by toll-like receptor 5 influences long-term gut microbiota composition. Nature. (2018) 560:489–93. 10.1038/s41586-018-0395-5

  • 78.

    ChassaingBLeyREGewirtzAT. Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice. Gastroenterology. (2014) 147:1363–77.e17. 10.1053/j.gastro.2014.08.033

  • 79.

    ChassinCKocurMPottJDuerrCUGütleDLotzMet al. miR-146a mediates protective innate immune tolerance in the neonate intestine. Cell Host Microbe. (2010) 8:358–68. 10.1016/j.chom.2010.09.005

  • 80.

    KnightsDSilverbergMSWeersmaRKGeversDDijkstraGHuangHet al. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med. (2014) 6:107. 10.1186/s13073-014-0107-1

  • 81.

    GoethelATurpinWRouquierSZanelloGRobertsonSJStreutkerCJet al. Nod2 influences microbial resilience and susceptibility to colitis following antibiotic exposure. Mucosal Immunol. (2019) 12:720–32. 10.1038/s41385-018-0128-y

  • 82.

    Moltzau AndersonJLipinskiSSommerFPanWHBoulardORehmanAet al. NOD influences trajectories of intestinal microbiota recovery after antibiotic perturbation. Cell Mol Gastroenterol Hepatol. (2020) 10:365–89. 10.1016/j.jcmgh.2020.03.008

  • 83.

    ZhangYHuangRChengMWangLChaoJLiJet al. Gut microbiota from NLRP3-deficient mice ameliorates depressive-like behaviors by regulating astrocyte dysfunction via circHIPK2. Microbiome. (2019) 7:116. 10.1186/s40168-019-0733-3

  • 84.

    ElinavEStrowigTKauALHenao-MejiaJThaissCABoothCJet al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. (2011) 145:745–57. 10.1016/j.cell.2011.04.022

  • 85.

    WlodarskaMThaissCANowarskiRHenao-MejiaJZhangJPBrownEMet al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell. (2014) 156:1045–59. 10.1016/j.cell.2014.01.026

  • 86.

    MamantopoulosMRonchiFVan HauwermeirenFVieira-SilvaSYilmazBMartensLet al. Nlrp6- and ASC-dependent inflammasomes do not shape the commensal gut microbiota composition. Immunity. (2017) 47:339–48.e4. 10.1016/j.immuni.2017.07.011

  • 87.

    LemirePRobertsonSJMaughanHTattoliIStreutkerCJPlatnichJMet al. The NLR protein NLRP does not impact gut microbiota composition. Cell Rep. (2017) 21:3653–61. 10.1016/j.celrep.2017.12.026

  • 88.

    GálvezEJCIljazovicAGronowAFlavellRStrowigT. Shaping of intestinal microbiota in Nlrp6- and Rag2-deficient mice depends on community structure. Cell Rep. (2017) 21:3914–26. 10.1016/j.celrep.2017.12.027

  • 89.

    SalzmanNHHungKHaribhaiDChuHKarsson-SjobergJAmirEet al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol. (2010) 11:76–83. 10.1038/ni.1825

  • 90.

    LehotzkyREPartchCLMukherjeeSCashHLGoldmanWEGardnerKHet al. Molecular basis for peptidoglycan recognition by a bactericidal lectin. Proc Natl Acad Sci USA. (2010) 107:7722–7. 10.1073/pnas.0909449107

  • 91.

    CashHLWhithamCVBehrendtCLHooperLV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. (2006) 313:1126–30. 10.1126/science.1127119

  • 92.

    MukherjeeSZhengHDerebeMGCallenbergKMPartchCLRollinsDet al. Antibacterial membrane attack by a pore-forming intestinal C- type lectin. Nature. (2014) 505:103–7. 10.1038/nature12729

  • 93.

    WangLFoutsDEStärkelPHartmannPChenPLlorenteCet al. Intestinal REG lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe. (2016) 19:227–39. 10.1016/j.chom.2016.01.003

  • 94.

    DarnaudMDos SantosAGonzalezPAuguiSLacosteCDesterkeCet al. Enteric delivery of regenerating family member 3 alpha alters the intestinal microbiota and controls inflammation in mice with colitis. Gastroenterology. (2018) 154:1009–23.e14. 10.1053/j.gastro.2017.11.003

  • 95.

    SonnenburgJLXuJLeipDDChenCHWestoverBPWeatherfordJet al. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science. (2005) 307:1955–9. 10.1126/science.1109051

  • 96.

    PngCWLindénSKGilshenanKSZoetendalEGMcSweeneyCSSlyLIet al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. (2010) 105:2420–8. 10.1038/ajg.2010.281

  • 97.

    KashyapPCMarcobalAUrsellLKSmitsSASonnenburgEDCostelloEKet al. Genetically dictated change in host mucus carbohydrate landscape exerts a diet-dependent effect on the gut microbiota. Proc Natl Acad Sci USA. (2013) 110:17059–64. 10.1073/pnas.1306070110

  • 98.

    SommerFAdamNJohanssonMEVXiaLHanssonGCBäckhedF. Altered mucus glycosylation in core O-glycan-deficient mice affects microbiota composition and intestinal architecture. PLoS ONE. (2014) 9:e85254. 10.1371/journal.pone.0085254

  • 99.

    JørgensenSFTroseidMKummenMAnmarkrudJAMichelsenAEOsnesLTet al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol. (2016) 9:1455–65. 10.1038/mi.2016.18

  • 100.

    JørgensenSFHolmKMacphersonMEStorm-LarsenCKummenMFevangBet al. Selective IgA deficiency in humans is associated with reduced gut microbial diversity. J Allergy Clin Immunol. (2019) 143:1969–71.e11. 10.1016/j.jaci.2019.01.019

  • 101.

    SterlinDFieschiCMalphettesMLarsenMGorochovGFadlallahJ. Immune/microbial interface perturbation in human IgA deficiency. Gut Microbes. (2019) 10:429–33. 10.1080/19490976.2018.1546520

  • 102.

    DuCTGaoWMaKYuSXLiNYanSQet al. MicroRNA-146a deficiency protects against listeria monocytogenes infection by modulating the gut microbiota. Int J Mol Sci. (2018) 19:993. 10.3390/ijms19040993

  • 103.

    LiuSda CunhaAPRezendeRMCialicRWeiZBryLet al. The host shapes the gut microbiota via fecal microRNA. Cell Host Microbe. (2016) 19:32–43. 10.1016/j.chom.2015.12.005

  • 104.

    MoloneyGMViolaMFHobanAEDinanTGCryanJF. Faecal microRNAs: indicators of imbalance at the host-microbe interface?Benef Microbes. (2018) 9:175–83. 10.3920/BM2017.0013

  • 105.

    Le DoareKHolderBBassettAPannarajPS. Mother's milk: a purposeful contribution to the development of the infant microbiota and immunity. Front Immunol. (2018) 9:361. 10.3389/fimmu.2018.00361

  • 106.

    RognumTOThraneRSStoltenbergLVegeÅBrandtzaegP. Development of intestinal mucosal immunity in fetal life and the first postnatal months. Pediatr Res. (1992) 32:145–8. 10.1203/00006450-199208000-00003

  • 107.

    PabstOCerovicVHornefM. Secretory IgA in the coordination of establishment and maintenance of the microbiota. Trends Immunol. (2016) 37:287–96. 10.1016/j.it.2016.03.002

  • 108.

    PhaliponACardonaAKraehenbuhlJPEdelmanLSansonettiPJCorthésyB. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity. (2002) 17:107–15. 10.1016/S1074-7613(02)00341-2

  • 109.

    RogierEWFrantzALBrunoMEKaetzelCS. Secretory IgA is concentrated in the outer layer of colonic mucus along with gut bacteria. Pathogens. (2014) 3:390–403. 10.3390/pathogens3020390

  • 110.

    LiHLimenitakisJPFuhrerTGeukingMBLawsonMAWyssMet al. The outer mucus layer hosts a distinct intestinal microbial niche. Nat Commun. (2015) 6:8292. 10.1038/ncomms9292

  • 111.

    BodeL. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. (2012) 22:1147–62. 10.1093/glycob/cws074

  • 112.

    KunzCMeyerCColladoMCGeigerLGarcía-MantranaIBertua-RíosBet al. Influence of gestational age, secretor, and Lewis blood group status on the oligosaccharide content of human milk. J Pediatr Gastroenterol Nutr. (2017) 64:789–98. 10.1097/MPG.0000000000001402

  • 113.

    Cabrera-RubioRKunzCRudloffSGarcía-MantranaICrehuá-GaudizaEMartínez-CostaCet al. Association of maternal secretor status and human milk oligosaccharides with milk microbiota: an observational pilot study. J Pediatr Gastroenterol Nutr. (2019) 68:256–63. 10.1097/MPG.0000000000002216

  • 114.

    MantheyCFAutranCAEckmannLBodeL. Human milk oligosaccharides protect against enteropathogenic Escherichia coli attachment in vitro and EPEC colonization in suckling mice. J Pediatr Gastroenterol Nutr. (2014) 58:165–8. 10.1097/MPG.0000000000000172

  • 115.

    HeYLiuSLeoneSNewburgDS. Human colostrum oligosaccharides modulate major immunologic pathways of immature human intestine. Mucosal Immunol. (2014) 7:1326–39. 10.1038/mi.2014.20

  • 116.

    HeYLiuSKlingDELeoneSLawlorNTHuangYet al. The human milk oligosaccharide 2'-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation. Gut. (2016) 65:33–46. 10.1136/gutjnl-2014-307544

  • 117.

    SodhiCPWipfPYamaguchiYFultonWBKovlerMNiñoDFet al. The human milk oligosaccharides 2'-fucosyllactose and 6'-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling. Pediatr Res. (2020). 10.1038/s41390-020-0852-3. [Epub ahead of print].

  • 118.

    LaymanDKLönnerdalBFernstromJD. Applications for α-lactalbumin in human nutrition. Nutr Rev. (2018) 76:444–60. 10.1093/nutrit/nuy004

  • 119.

    BrückWMRedgraveMTuohyKMLönnerdalBGraverholtGHernellOet al. Effects of bovine alpha-lactalbumin and casein glycomacropeptide-enriched infant formulae on faecal microbiota in healthy term infants. J Pediatr Gastroenterol Nutr. (2006) 43:673–9. 10.1097/01.mpg.0000232019.79025.8f

  • 120.

    RozéJCBarbarotSButelMJKapelNWaligora-DuprietAJDe MontgolfierIet al. An α-lactalbumin-enriched and symbiotic-supplemented v. a standard infant formula: a multicentre, double-blind, randomised trial. Br J Nutr. (2012) 107:1616–22. 10.1017/S000711451100479X

  • 121.

    DavidsonLALönnerdalB. Persistence of human milk proteins in the breast-fed infant. Acta Paediatr Scand. (1987) 76:733–40. 10.1111/j.1651-2227.1987.tb10557.x

  • 122.

    LönnerdalB. Bioactive proteins in breast milk. J Paediatr Child Health. (2013) 49 (Suppl. 1):1–7. 10.1111/jpc.12104

  • 123.

    WakabayashiHYamauchiKTakaseM. Inhibitory effects of bovine lactoferrin and lactoferricin B on Enterobacter sakazakii. Biocontrol Sci. (2008) 13:29–32. 10.4265/bio.13.29

  • 124.

    BellamyWTakaseMYamauchiKWakabayashiHKawaseKTomitaM. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta. (1992) 1121:130–6. 10.1016/0167-4838(92)90346-F

  • 125.

    UlvatneHSamuelsenØHauklandHHKrämerMVorlandLH. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett. (2004) 237:377–84. 10.1111/j.1574-6968.2004.tb09720.x

  • 126.

    BruniNCapucchioMTBiasibettiEPessioneECirrincioneSGiraudoLet al. Antimicrobial activity of lactoferrin-related peptides and applications in human and veterinary medicine. Molecules. (2016) 21:752. 10.3390/molecules21060752

  • 127.

    BrouwerCPJMRahmanMWellingMM. Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides. (2011) 32:1953–63. 10.1016/j.peptides.2011.07.017

  • 128.

    HentgesDJMarshWWPetschowBWThalWRCarterMK. Influence of infant diets on the ecology of the intestinal tract of human flora-associated mice. J Pediatr Gastroenterol Nutr. (1992) 14:146–52. 10.1097/00005176-199202000-00005

  • 129.

    MastromarinoPCapobiancoDCampagnaGLaforgiaNDrimacoPDileoneAet al. Correlation between lactoferrin and beneficial microbiota in breast milk and infant's feces. Biometals. (2014) 27:1077–86. 10.1007/s10534-014-9762-3

  • 130.

    BalmerSEScottPHWhartonBA. Diet and faecal flora in the newborn: lactoferrin. Arch Dis Child. (1989) 64:1685–90. 10.1136/adc.64.12.1685

  • 131.

    RobertsAKChiericiRSawatzkiGHillMJVolpatoSVigiV. Supplementation of an adapted formula with bovine lactoferrin: I. effect on the faecal flora. Acta Paediatr. (1992) 81:119–24. 10.1111/j.1651-2227.1992.tb12186.x

  • 132.

    ShermanMPShermanJArcinueRNiklasV. Randomized control trial of human recombinant lactoferrin: a substudy reveals effects on the fecal microbiome of very low birth weight infants. J Pediatr. (2016) 173:S37–42. 10.1016/j.jpeds.2016.02.074

  • 133.

    CastanetMCostalosCHaidenNHascoetJMBergerBSprengerNet al. Early effect of supplemented infant formulae on intestinal biomarkers and microbiota: a randomized clinical trial. Nutrients. (2020) 12:1481. 10.3390/nu12051481

  • 134.

    GriffithsEADuffyLCSchanbacherFLDryjaDLeavensANeiswanderRLet al. In vitro growth responses of bifidobacteria and enteropathogens to bovine and human lactoferrin. Dig Dis Sci. (2003) 48:1324–32. 10.1023/A:1024111310345

  • 135.

    WadaYLönnerdalB. Bioactive peptides derived from human milk proteins - mechanisms of action. J Nutr Biochem. (2014) 25:503–14. 10.1016/j.jnutbio.2013.10.012

  • 136.

    MancinelliRRosaLCutoneALepantoMSFranchittoAOnoriPet al. Viral hepatitis and iron dysregulation: molecular pathways and the role of lactoferrin. Molecules. (2020) 25:1997. 10.3390/molecules25081997

  • 137.

    LiaoYJiangRLönnerdalB. Biochemical and molecular impacts of lactoferrin on small intestinal growth and development during early life. Biochem Cell Biol. (2012) 90:476–84. 10.1139/o11-075

  • 138.

    LegrandD. Overview of lactoferrin as a natural immune modulator. J Pediatr. (2016) 173:S10–5. 10.1016/j.jpeds.2016.02.071

  • 139.

    VoglTLeukertNBarczykKStrupatKRothJ. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochim Biophys Acta. (2006) 1763:1298–306. 10.1016/j.bbamcr.2006.08.028

  • 140.

    LässerCAlikhaniVSEkströmKEldhMParedesPTBossiosAet al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med. (2011) 9:9. 10.1186/1479-5876-9-9

  • 141.

    KarlssonORodosthenousRSJaraCBrennanKJWrightROBaccarelliAAet al. Detection of long non-coding RNAs in human breastmilk extracellular vesicles: implications for early child development. Epigenetics. (2016) 11:721–9. 10.1080/15592294.2016.1216285

  • 142.

    van HerwijnenMJZonneveldMIGoerdayalSNolte-'t HoenENGarssenJStahlBet al. Comprehensive proteomic analysis of human milk-derived extracellular vesicles unveils a novel functional proteome distinct from other milk components. Mol Cell Proteomics. (2016) 15:3412–23. 10.1074/mcp.M116.060426

  • 143.

    KosakaNIzumiHSekineKOchiyaT. microRNA as a new immune-regulatory agent in breast milk. Silence. (2010) 1:7. 10.1186/1758-907X-1-7

  • 144.

    ZhouQLiMWangXLiQWangTZhuQet al. Immune-related microRNAs are abundant in breast milk exosomes. Int J Biol Sci. (2012) 8:118–23. 10.7150/ijbs.8.118

  • 145.

    KimSYYiDY. Analysis of the human breast milk microbiome and bacterial extracellular vesicles in healthy mothers. Exp Mol Med. (2020) 52:1288–97. 10.20944/preprints202004.0404.v1

  • 146.

    FitzstevensJLSmithKCHagadornJICaimanoMJMatsonAPBrownellEA. Systematic review of the human milk microbiota. Nutr Clin Pract. (2017) 32:354–64. 10.1177/0884533616670150

  • 147.

    ChichlowskiMDe LartigueGGermanJBRaybouldHEMillsDA. Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function. J Pediatr Gastroenterol Nutr. (2012) 55:321–7. 10.1097/MPG.0b013e31824fb899

  • 148.

    SelaDAMillsDA. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. Trends Microbiol. (2010) 18:298–307. 10.1016/j.tim.2010.03.008

  • 149.

    Díaz-RoperoMPMartínRSierraSLara-VillosladaFRodríguezJMXausJet al. Two Lactobacillus strains, isolated from breast milk, differently modulate the immune response. J Appl Microbiol. (2007) 102:337–43. 10.1111/j.1365-2672.2006.03102.x

  • 150.

    OlivaresMDíaz-RoperoMPMartínRRodríguezJMXausJ. Antimicrobial potential of four Lactobacillus strains isolated from breast milk. J Appl Microbiol. (2006) 101:72–9. 10.1111/j.1365-2672.2006.02981.x

  • 151.

    MoossaviSSepehriSRobertsonBBodeLGorukSFieldCJet al. Composition and variation of the human milk microbiota are influenced by maternal and early-life factors. Cell Host Microbe. (2019) 25:324–35.e4. 10.1016/j.chom.2019.01.011

  • 152.

    LeMay-NedjelskiLButcherJLeySHAsburyMRHanleyAJKissAet al. Examining the relationship between maternal body size, gestational glucose tolerance status, mode of delivery and ethnicity on human milk microbiota at three months post-partum. BMC Microbiol. (2020) 20:219. 10.1186/s12866-020-01901-9

  • 153.

    BeghettiIBiagiEMartiniSBrigidiPCorvagliaLAcetiA. Human milk's hidden gift: implications of the milk microbiome for preterm infants' health. Nutrients. (2019) 11:2944. 10.3390/nu11122944

  • 154.

    Cabrera-RubioRColladoMCLaitinenKSalminenSIsolauriEMiraA. The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. Am J Clin Nutr. (2012) 96:544–51. 10.3945/ajcn.112.037382

  • 155.

    ColladoMCLaitinenKSalminenSIsolauriE. Maternal weight and excessive weight gain during pregnancy modify the immunomodulatory potential of breast milk. Pediatr Res. (2012) 72:77–85. 10.1038/pr.2012.42

  • 156.

    AndreasNJHydeMJGaleCParkinsonJRJeffriesSHolmesEet al. Effect of maternal body mass index on hormones in breast milk: a systematic review. PLoS ONE. (2014) 9:e115043. 10.1371/journal.pone.0115043

  • 157.

    MulliganCMFriedmanJE. Maternal modifiers of the infant gut microbiota: metabolic consequences. J Endocrinol. (2017) 235:R1–12. 10.1530/JOE-17-0303

  • 158.

    AjslevTAAndersenCSGamborgMSorensenTIJessT. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes. (2011) 35:522–9. 10.1038/ijo.2011.27

  • 159.

    TangMFrankDNSherlockLIrDRobertsonCEKrebsNF. Effect of vitamin E with therapeutic iron supplementation on iron repletion and gut microbiome in US iron deficient infants and toddlers. J Pediatr Gastroenterol Nutr. (2016) 63:379–85. 10.1097/MPG.0000000000001154

  • 160.

    KnightLCWangMDonovanSMDilgerRN. Early-life iron deficiency and subsequent repletion alters development of the colonic microbiota in the pig. Front Nutr. (2019) 6:120. 10.3389/fnut.2019.00120

  • 161.

    DoschNCGuslitsEFWeberMBMurraySEHaBCoeCLet al. Maternal obesity affects inflammatory and iron indices in umbilical cord blood. J Pediatr. (2016) 172:20–8. 10.1016/j.jpeds.2016.02.023

  • 162.

    JonesADZhaoGJiangYPZhouMXuGKacirotiNet al. Maternal obesity during pregnancy is negatively associated with maternal and neonatal iron status. Eur J Clin Nutr. (2016) 70:918–24. 10.1038/ejcn.2015.229

  • 163.

    Simonyté SjödinKDomellöfMLagerqvistCHernellOLönnerdalBSzymlek-GayEAet al. Administration of ferrous sulfate drops has significant effects on the gut microbiota of iron-sufficient infants: a randomised controlled study. Gut. (2019) 68:2095–7. 10.1136/gutjnl-2018-316988

  • 164.

    DostalAFehlbaumSChassardCZimmermannMBLacroixC. Low iron availability in continuous in vitro colonic fermentations induces strong dysbiosis of the child gut microbial consortium and a decrease in main metabolites. FEMS Microbiol Ecol. (2013) 83:161–75. 10.1111/j.1574-6941.2012.01461.x

  • 165.

    DostalABaumgartnerJRiesenNChassardCSmutsCMZimmermannMBet al. Effects of iron supplementation on dominant bacterial groups in the gut, faecal SCFA and gut inflammation: a randomised, placebo-controlled intervention trial in South African children. Br J Nutr. (2014) 112:547–56. 10.1017/S0007114514001160

  • 166.

    DostalALacroixCBircherLPhamVTFolladorRZimmermannMBet al. Iron modulates butyrate production by a child gut microbiota in vitro. mBio. (2015) 6:e01453–15. 10.1128/mBio.01453-15

  • 167.

    ForgieAJDrallKMBourqueSLFieldCJKozyrskyjALWillingBP. The impact of maternal and early life malnutrition on health: a diet-microbe perspective. BMC Med. (2020) 18:135. 10.1186/s12916-020-01584-z

  • 168.

    RusuIGSuharoschiRVodnarDCPopCRSocaciSAVulturarRet al. Iron supplementation influence on the gut microbiota and probiotic intake effect in iron deficiency-a literature-based review. Nutrients. (2020) 12:E1993. 10.3390/nu12071993

  • 169.

    IramNMildnerPriorMPetzelbauerPFialaCHackerSet al. Age-related changes in expression and function of Toll-like receptors in human skin. Development. (2012) 139:4210–9. 10.1242/dev.083477

  • 170.

    RachmilewitzDKatakuraKKarmeliFHayashiTReinusCRudenskyBet al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. (2004) 126:520–8. 10.1053/j.gastro.2003.11.019

  • 171.

    FukataMMichelsenKSEriRThomasLSHuBLukasekKet al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol. (2005) 288:G1055–65. 10.1152/ajpgi.00328.2004

  • 172.

    JillingTSimonDLuJMengFJLiDSchyRet al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol. (2006) 177:3273–82. 10.4049/jimmunol.177.5.3273

  • 173.

    ZaphCTroyAETaylorBCBerman-BootyLDGuildKJDuYet al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature. (2007) 446:552–6. 10.1038/nature05590

  • 174.

    Vijay-KumarMSandersCJTaylorRTKumarAAitkenJDSitaramanSVet al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest. (2007) 117:3909–21. 10.1172/JCI33084

  • 175.

    NenciABeckerCWullaertAGareusRvan LooGDaneseSet al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. (2007) 446:557–61. 10.1038/nature05698

  • 176.

    LeaphartCLCavalloJGribarSCCetinSLiJBrancaMFet al. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. Immunol. (2007) 179:4808–20. 10.4049/jimmunol.179.7.4808

  • 177.

    GribarSCSodhiCPRichardsonWMAnandRJGittesGKBrancaMFet al. Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. J Immunol. (2009) 182:636–46. 10.4049/jimmunol.182.1.636

  • 178.

    AsquithMJBoulardOPowrieFMaloyKJ. Pathogenic and protective roles of MyD88 in leukocytes and epithelial cells in mouse models of inflammatory bowel disease. Gastroenterology. (2010) 139:519–29, 529.e1–2. 10.1053/j.gastro.2010.04.045

  • 179.

    ZhouWCaoQPengYZhangQJCastrillonDHDePinhoRAet al. FoxO4 inhibits NF-kappaB and protects mice against colonic injury and inflammation. Gastroenterology. (2009) 137:1403–14. 10.1053/j.gastro.2009.06.049

  • 180.

    StockingerSDuerrCUFuldeMDolowschiakTPottJYangIet al. TRIF signaling drives homeostatic intestinal epithelial antimicrobial peptide expression. J Immunol. (2014) 193:4223–34. 10.4049/jimmunol.1302708

  • 181.

    KanagaveluSFloresCTerminiJMRiveronRRomeroLChungKet al. TIR-domain-containing adapter-inducing interferon-β. (TRIF) regulates Th17-mediated intestinal immunopathology in colitis. Mucosal Immunol. (2015) 8:296–306. 10.1038/mi.2014.67

  • 182.

    VoglTTenbrockKLudwigSLeukertNEhrhardtCvan Zoelenet al. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. (2007) 13:1042–9. 10.1038/nm1638

  • 183.

    BauerCDuewellPMayerCLehrHAFitzgeraldKADauerMet al. Colitis induced in mice with dextran sulfate sodium. (DSS) is mediated by the NLRP3 inflammasome. Gut. (2010) 59:1192–9. 10.1136/gut.2009.197822

  • 184.

    SiegmundBLehrHAFantuzziGDinarelloC A. IL-1 beta -converting enzyme. (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA. (2001) 98:13249–54. 10.1073/pnas.231473998

  • 185.

    ZakiMHBoydKLVogelPKastanMBLamkanfiMKannegantiTDet al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. (2010) 32:379–91. 10.1016/j.immuni.2010.03.003

  • 186.

    BrozPNewtonKLamkanfiMMariathasanSDixitVMMonackDM. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med. (2010) 207:1745–55. 10.1084/jem.20100257

  • 187.

    HirotaSANgJLuengAKhajahMParharKLiYet al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis. (2011) 17:1359–72. 10.1002/ibd.21478

  • 188.

    KimYGKamadaNShawMHWarnerNChenGYFranchiLet al. The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity. (2011) 34:769–80. 10.1016/j.immuni.2011.04.013

  • 189.

    OguraYBonenDKInoharaNNicolaeDLChenFFRamosRet al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. (2001) 411:603–6. 10.1038/35079114

  • 190.

    HugotJPChamaillardMZoualiHLesageSCézardJPBelaicheJet al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. (2001) 411:599–603. 10.1038/35079107

  • 191.

    MallowEBHarrisASalzmanNRussellJPDeBerardinisRJRuchelliEet al. Human enteric defensins. gene structure and developmental expression. J Biol Chem. (1996) 271:4038–45. 10.1074/jbc.271.8.4038

  • 192.

    OuelletteAJGrecoRMJamesMFrederickDNaftilanJFallonJT. Developmental regulation of cryptdin, a corticostatin/defensin precursor mRNA in mouse small intestinal crypt epithelium. J Cell Biol. (1989) 108:1687–95. 10.1083/jcb.108.5.1687

  • 193.

    CunliffeRNMahidaYR. Expression and regulation of antimicrobial peptides in the gastrointestinal tract. J Leukoc Biol. (2004) 75:49–58. 10.1189/jlb.0503249

  • 194.

    GanzT. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. (2003) 3:710–20. 10.1038/nri1180

  • 195.

    HazlettLWuM. Defensins in innate immunity. Cell Tissue Res. (2011) 343:175–88. 10.1007/s00441-010-1022-4

  • 196.

    BlythGADConnorsLFodorCCoboER. The network of colonic host defense peptides as an innate immune defense against enteropathogenic bacteria. Front Immunol. (2020) 11:965. 10.3389/fimmu.2020.00965

  • 197.

    SchauberJSvanholmCTermenSIfflandKMenzelTet al. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut. (2003) 52:735–41. 10.1136/gut.52.5.735

  • 198.

    O'NeilDAPorterEMElewautDAndersonGMEckmannLGanzTet al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol. (1999) 163:6718–24.

  • 199.

    ChairatanaPNolanEM. Defensins, lectins, mucins, and secretory immunoglobulin A: microbe-binding biomolecules that contribute to mucosal immunity in the human gut. Crit Rev Biochem Mol Biol. (2017) 52:45–56. 10.1080/10409238.2016.1243654

  • 200.

    FadlallahJEl KafsiHSterlinDJusteCParizotCDorghamKet al. Microbial ecology perturbation in human IgA deficiency. Sci Transl Med. (2018) 10:eaan1217. 10.1126/scitranslmed.aan1217

  • 201.

    CatanzaroJRStraussJDBieleckaAPortoAFLoboFMUrbanAet al. IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. Sci Rep. (2019) 9:13574. 10.1038/s41598-019-49923-2

  • 202.

    SarsharMScribanoDAmbrosiCPalamaraATMasottiA. Fecal microRNAs as innovative biomarkers of intestinal diseases and effective players in host-microbiome interactions. Cancers. (2020) 12:E2174. 10.3390/cancers12082174

  • 203.

    FreedmanJEGersteinMMickERozowskyJLevyDKitchenRet al. Diverse human extracellular RNAs are widely detected in human plasma. Nat Commun. (2016) 7:11106. 10.1038/ncomms11902

  • 204.

    PisitkunTShenRFKnepperMA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. (2004) 101:13368–73. 10.1073/pnas.0403453101

  • 205.

    ChassinCHempelCStockingerSDupontAKüblerJFWedemeyerJet al. MicroRNA-146a-mediated downregulation of IRAK1 protects mouse and human small intestine against ischemia/reperfusion injury. EMBO Mol Med. (2012) 4:1308–19. 10.1002/emmm.201201298

  • 206.

    JiYLiXZhuYLiNZhangNNiuM. Faecal microRNA as a biomarker of the activity and prognosis of inflammatory bowel diseases. Biochem Biophys Res Commun. (2018) 503:2443–50. 10.1016/j.bbrc.2018.06.174

Summary

Keywords

neonatal mucosal immunity, developing microbiota, shaping of microbiota, gut microbial colonization, host factors

Citation

Pirr S and Viemann D (2020) Host Factors of Favorable Intestinal Microbial Colonization. Front. Immunol. 11:584288. doi: 10.3389/fimmu.2020.584288

Received

17 July 2020

Accepted

09 September 2020

Published

07 October 2020

Volume

11 - 2020

Edited by

Philipp Henneke, University of Freiburg, Germany

Reviewed by

Zhanju Liu, Tongji University, China; Laura Baldomà, University of Barcelona, Spain

Updates

Copyright

© 2020 Pirr and Viemann.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sabine Pirr

This article was submitted to Nutritional Immunology, a section of the journal Frontiers in Immunology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics